BACE2 antibody detects human amyloid-beta (Abeta) plaque. Accumulation of the amyloid-beta (Abeta) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. Abeta peptide is generated by proteolytic cleavage of the beta-amyloid protein precursor (APP) at beta- and gamma-sites by proteases. The long-sought beta-secretase was recently identified by several groups independently and designated beta-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2). A BACE homolog was recently cloned and designated BACE2, Asp1, DRAP (for Down region aspartic protease), and memapsin 1. BACE2 also cleaves APP at beta-site and at a different site within Abeta. BACE2 locates on chromosome 21q22.3, the so-called ‘Down critical region’, suggesting that BACE2 and Abeta may also contribute to the pathogenesis of Down syndrome. Anti-BACE2 antibodies are ideal for investigators involved in Neuroscience and DNA Damage and Repair.
- Recommended Dilutions: Western Blot: 0.5-1 ug/mL; contains 0.01% (w/v) Sodium Azide
Type: Primary
Antigen: BACE2
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope: Center
Host: Rabbit
Isotype:
Reactivity: Human, Mouse, Rat